Skip to main content
Medical information Clinical review pending

Cytogenetics

Neuroblastoma Profile 24 Hour Urine Test

The Neuroblastoma Profile 24 Hour Urine Test helps detect neuroblastoma, a cancer mainly affecting children, by measuring Vanillyl Mandelic Acid (VMA) and Homovanillic Acid (HVA) levels in a 24-hour urine sample. This test aids in early diagnosis and guides treatment decisions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
A 24-hour urine collection. Specific container provided by the laboratory.
Results
Confirm with the laboratory before booking.
Preparation
Avoid L-Dopa, Theophylline, Chocolate, Vanilla, Bananas, Alcoholic beverages, Tea/Coffee, Tobacco, and strenuous exercise for at least 72 hours before and during collection. Confirm specific dietary and activity restrictions with the laboratory before starting collection.
Test priceKSh 17,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Neuroblastoma Profile 24 Hour Urine Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Children with symptoms suggestive of neuroblastoma (e.g., abdominal mass, bone pain, unexplained weight loss).
  • ✓Monitoring children with a known history of neuroblastoma.
  • ✓Screening children with a family history of neuroblastoma.
  • ✓Evaluating children with unexplained fatigue or lethargy.
  • ✓Assessing children with abdominal swelling or pain.
02

In plain language

What this test helps you understand

This test aids in the diagnosis and monitoring of neuroblastoma by measuring levels of specific metabolites (VMA and HVA) in urine, which can be elevated in patients with this condition.
The Neuroblastoma Profile 24 Hour Urine Test is an important tool in the early detection and diagnosis of neuroblastoma, a type of cancer that most often affects infants and young children. This test analyzes specific substances in urine collected over a 24-hour period to help doctors assess for the presence of this cancer.

This test measures the levels of two key metabolites in the urine:

* Vanillyl Mandelic Acid (VMA) * Homovanillic Acid (HVA)

Elevated levels of VMA and HVA can be indicators of neuroblastoma, providing valuable information to healthcare providers for diagnosis and management.

This test is typically recommended for children showing symptoms potentially related to neuroblastoma, such as abdominal pain or swelling, unexplained weight loss, bone pain, or persistent fatigue. Children with a family history of neuroblastoma may also be advised to undergo this test.

Benefits of this test include the potential for early detection, which is critical for successful treatment outcomes. The test uses a non-invasive urine sample, making it suitable for young patients. Results help guide oncologists in planning the appropriate course of care.

Discuss your results with your healthcare provider. Elevated levels may require further investigation to confirm a diagnosis. Confirm with the laboratory before booking.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationAvoid L-Dopa, Theophylline, Chocolate, Vanilla, Bananas, Alcoholic beverages, Tea/Coffee, Tobacco, and strenuous exercise for at least 72 hours before and during collection. Confirm specific dietary and activity restrictions with the laboratory before starting collection.
SampleA 24-hour urine collection. Specific container provided by the laboratory.
MethodologyChromatographic analysis (e.g., HPLC) to measure the concentration of VMA and HVA in the urine sample.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
Elevated VMA/HVA levels are not specific to neuroblastoma and can be caused by other conditions or factors. False negatives can occur. Further diagnostic tests are usually required to confirm a diagnosis.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Neuroblastoma is a type of cancer that develops from immature nerve cells, most commonly found in infants and young children.
Collecting urine over 24 hours provides a more accurate measurement of VMA and HVA levels compared to a single spot sample.
VMA (Vanillyl Mandelic Acid) and HVA (Homovanillic Acid) are substances produced when the body breaks down catecholamines. Elevated levels can be associated with neuroblastoma.
The urine collection itself is non-invasive. However, collecting urine from infants or young children over 24 hours requires careful planning and assistance.
Abnormal results require further investigation by a doctor. They may order additional tests to confirm a diagnosis and determine the next steps in care.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp